Endogenic Primo

What is methenolone enanthate?

Methenolone enanthate (chemically 1-methyl-5α-androst-1-ene-17β-ol-3-one, esterified with heptanoic acid at the 17β position) is a long-acting ester of methenolone, a derivative of dihydrotestosterone (DHT). Structurally, the molecule is based on DHT with a methyl group in position 1 and a double bond between carbon-1 and carbon-2 in the A ring. This combination produces two crucial pharmacological consequences. The aromatase enzyme cannot act on the molecule, which means that estrogenic conversion is completely absent, and the binding to the androgen receptor (AR) becomes noticeably strong, even though the absolute androgenic potency measured in classic test systems is moderate.

The substance was developed by Schering in the early 1960s and introduced in 1962 under the trade names Primobolan (oral form, methenolone acetate) and Primobolan Depot (injection, methenolone enanthate). The original clinical indications included anemias of various etiologies, cachexia in chronic diseases, postoperative convalescence and certain forms of muscle wasting in prematurely born children. The preparation is still registered as a medicine in several countries, especially in German-speaking regions and in parts of Latin America, which is unusual for anabolic steroids.

The enant ester, with a heptanoic acid chain of seven carbons, gives the preparation a half-life of around 10–14 days and a prolonged release profile from the injection depot. The ratio of anabolic to androgenic activity is given in classic literature as approximately 88:44 with testosterone as a reference of 100:100 — a mild anabolic component and low androgenic character. In pharmacological literature, methenolone is often described as one of the milder anabolic compounds in the class.

How does methenolone enanthate work?

After intramuscular injection, an oil depot is formed in the muscle tissue from which methenolone enanthate slowly diffuses out into the blood. Plasma esterases hydrolyze the ester bond and free methenolone is released. The long ester provides a stable and extended serum profile without pronounced peaks between injections.

Free methenolone binds to the androgen receptor (AR), forms a ligand-receptor complex and is transported to the cell nucleus, where it controls the transcription of genes linked to protein synthesis and nitrogen balance. Two structural features shape the molecule's profile. Since methenolone is based on the DHT skeleton, it is completely resistant to aromatization — no estrogenic activity via the aromatase enzyme occurs. At the same time, the molecule is insensitive to 5α-reductase, because it is in the 5α-reduced form right from the start, and is thus not exposed to further activation in the skin, prostate or hair follicles.

A particular property concerns the molecule's immunological impact. Clinical literature from use in pediatric anemia and in HIV-associated cachexia has documented relative preservation of T-cell function and immunoglobulin levels in treated patients, something not seen as clearly with other anabolic steroids. The mechanism is not fully understood but is linked in the literature to methenolone's low aromatization and moderate androgenic character.

What can methenolone enanthate potentially affect?

In the available pharmacological literature, clinical studies from the 1960s and 1970s as well as later epidemiological research, several physiological systems in which methenolone shows an imprint reappear:

• Muscle tissue — activation of AR in myocytes increases protein synthesis and moderately improves nitrogen balance. The effect is characteristically "dry" because estrogenic water retention is missing.

• Erythropoiesis — historically, anemias were the main indication. Stimulation of the kidneys' EPO production results in rising hematocrit and hemoglobin concentration in a dose-dependent manner.

• Immune System — clinical data from the treatment of pediatric aplastic anemia and HIV-related cachexia show preserved T-cell function and immunoglobulin profile in treated patients.

• Connective tissue and skin — The DHT derivative has some effect on tissues rich in androgen receptors, but more moderate than other DHT derivatives due to the low androgenic potential.

• Hypothalamus-pituitary-gonadal axis (HPG) — like other exogenous androgens, methenolone via negative feedback lowers the secretion of GnRH as well as LH and FSH with consequent downregulation of endogenous testosterone production.

• Lipid Metabolism — DHT derivatives shift the lipid profile more markedly than aromatizing compounds, because the liver lacks the counterbalance that estrogen normally exerts on HDL synthesis.

Potential side effects of methenolone enanthate

The side effect profile of methenolone enanthate is considered in pharmacological literature to be milder than that of most other anabolic steroids. The absence of estrogenic side effects, the low androgenic potential and relatively mild effects on the liver and immune system are characteristic features. However, the profile is not free of adverse effects, and the long half-life means that any effects persist long after exposure has ended.

• Hormonal changes — prolonged suppression of the HPG axis with accompanying hypogonadism, decreased levels of LH, FSH, and endogenous testosterone, and impaired spermatogenesis. Recovery can take months.

• Cardiovascular effects — unfavorable shift in the lipid profile with lowered HDL and elevated LDL, moderately elevated blood pressure and, with prolonged exposure, risk of left ventricular hypertrophy.

• Hematological — rising hematocrit which, at extreme values, leads to increased blood viscosity and thromboembolic risk.

• Androgens — acne, seborrhea and oily skin occur, but in a milder form than with stronger DHT derivatives. Accelerated male pattern baldness in genetically predisposed individuals may occur.

• Hepatological — relatively mild burden because the enantaster is administered parenterally and bypasses first-pass metabolism, but liver enzyme values may be shifted with prolonged exposure.

• Psychic — mood swings, irritability and sleep disturbances occur, often in a milder form than with stronger anabolic compounds.

• In women — risk of virilization symptoms: voice deepening, hirsutism, clitoral hypertrophy and menstrual disorders. The risk is lower than with trenbolone or drostanolone but is not insignificant with prolonged exposure.

The overall side effect picture of methenolone enanthate — mild but not absent androgenic influence, lipid influence, HPG suppression and hematological shifts — means that clinical use is based on regular laboratory checks (lipid status, blood count, liver enzymes, hormone panel) and an individual assessment of the risk-benefit balance.